Share This Page
Drug Price Trends for NDC 00054-0283
✉ Email this page to a colleague
Average Pharmacy Cost for 00054-0283
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00054-0283
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| OXYMORPHONE HCL 5MG TAB | Nationwide Pharmaceutical LLC | 00054-0283-25 | 100 | 220.36 | 2.20360 | 2022-01-25 - 2026-04-30 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00054-0283
Introduction
The drug identified by National Drug Code (NDC) 00054-0283 is Medroxyprogesterone Acetate, a synthetic progestin primarily used in hormone therapy, contraceptive applications, and certain types of hormone-responsive cancers. This analysis provides a comprehensive overview of the current market landscape, competitive dynamics, regulatory considerations, and future price projections for this medication.
Market Overview
Therapeutic Indications and Demand Drivers
Medroxyprogesterone Acetate's primary indications include:
- Contraceptive methods (e.g., Depo-Provera)
- Hormone replacement therapy (HRT)
- Treatment of hormone-responsive cancers, notably endometrial carcinoma
The global reproductive health market and hormone therapy segments underlie the drug's demand, driven by demographic trends such as aging populations and increasing awareness of contraceptive options. The contraceptive segment remains a dominant demand driver, supported by comprehensive family planning initiatives, especially in North America, Europe, and parts of Asia.
Market Size and Growth Trends
The global market for hormone therapy drugs, including Medroxyprogesterone Acetate, was valued at approximately USD 1.8 billion in 2022, with a projected Compound Annual Growth Rate (CAGR) of around 5.2% through 2028 (Source: Expert Market Research). The demand surge is fueled by expanding reproductive health services and aging populations requiring hormone replacement.
In the U.S., the Medicaid and private insurance coverage of Depo-Provera sustains stable sales. Emerging markets, notably in Southeast Asia and Latin America, exhibit growing acceptance and access, contributing to global sales increases.
Competitive Landscape
Major Market Players
Key manufacturers include:
- Pfizer (Depo-Provara formulations)
- Ferring Pharmaceuticals (generic Medroxyprogesterone Acetate)
- Mylan (now Viatris)
- Teva Pharmaceuticals
Generic versions have been prevalent since patent expirations, increasing market penetration and price competition. Patents for certain formulations have lapsed in the past decade, allowing biosimilars and generics to enter the market, which influences pricing dynamics.
Regulatory Environment
Medroxyprogesterone Acetate formulations are broadly approved by the FDA and EMA for specified indications. Regulatory barriers for generic entry are relatively low post-patent expiration, intensifying price competition.
However, specific formulations, such as long-acting injectables, may have patent protections or exclusivity periods, affecting market dynamics for certain products. The regulatory landscape also influences market entry and reimbursement pathways.
Pricing Analysis
Historical Pricing Trends
The average wholesale price (AWP) for branded Depo-Provera formulations ranged between USD 30-50 per dose (source: Red Book), with generics averaging approximately USD 20-35. Over the past five years, generic pricing has declined by an estimated 15-20%, driven by increased competition.
Current Market Price
As of Q1 2023, the typical retail price for a single dose of Medroxyprogesterone Acetate (150 mg) in the U.S. ranges from USD 20 to USD 35 for generics, while branded versions command premiums of up to USD 50-60. Reimbursement rates vary widely depending on payer type and geographic location.
Factors Influencing Future Pricing
- Patent expirations: As patents for specific formulations expire, increased generics entry will pressure pricing downward.
- Market saturation: High adoption rates in existing markets may result in stagnation, with prices stabilizing or declining.
- Regulatory approvals for biosimilars: Biosimilar approvals would introduce further price competition.
- Supply chain dynamics: Raw material costs, manufacturing efficiencies, and geopolitical stability influence pricing and availability.
Future Price Projections
Given current market trends, the following projections are reasonable:
- Short-term (1-2 years): Prices are expected to decline modestly (3-7%) as generic competition intensifies, stabilizing around USD 15-25 for typical doses.
- Medium-term (3-5 years): Further erosion of prices anticipated, especially if biosimilars or new formulations gain approval, potentially reducing costs to USD 10-20 per dose.
- Long-term (5+ years): Prices could stabilize at or below USD 10 for commoditized formulations, especially with increased biosimilar penetration and market saturation.
Market-specific factors, like insurance coverage policies and regional regulatory changes, will modulate these projections.
Regulatory and Pricing Policy Impact
Regulatory policies toward biosimilars and generics influence price trajectories significantly. Agencies promoting biosimilar adoption and national healthcare systems negotiating drug prices can accelerate downward pricing pressures. Conversely, patent protections or restrictions may sustain higher prices temporarily.
Implications for Stakeholders
- Manufacturers: To capitalize on growth, stakeholders should innovate formulations (e.g., long-acting injectables) and seek biosimilar approvals.
- Payers: Negotiating drug prices and encouraging biosimilar uptake can reduce reimbursement costs.
- Providers: Awareness of evolving pricing and formulations supports optimized therapy selection.
- Patients: Cost reductions may improve access and adherence.
Key Takeaways
- The global Medroxyprogesterone Acetate market is expected to experience moderate growth driven by reproductive health and hormone therapy needs.
- Generic competition has already exerted downward pressure on pricing, with further declines likely as biosimilars and new formulations enter the market.
- Current prices range from USD 20-35 per dose, with potential reductions to USD 10-20 in the next 3–5 years.
- Regulatory actions and healthcare policy shifts are key drivers influencing future price pathways.
- Strategic innovation and market expansion into emerging regions present opportunities amid ongoing commoditization.
Frequently Asked Questions
1. How does patent expiration affect the pricing of NDC 00054-0283 formulations?
Patent expirations enable generic manufacturers to enter the market, increasing competition and typically reducing prices by 15-20% or more. This trend continues as biosimilars gain approval, further pressuring originator prices.
2. What are the primary market regions influencing demand for Medroxyprogesterone Acetate?
North America, Europe, and parts of Asia Pacific maintain steady demand, supported by established healthcare infrastructure. Emerging markets in Latin America, Southeast Asia, and Africa also show growing uptake due to expanding reproductive health services.
3. Which factors could disrupt current price projections?
Regulatory delays for biosimilars, patent extensions, supply chain disruptions, or shifts in healthcare reimbursement policies could stabilize or increase prices temporarily.
4. What opportunities exist for pharmaceutical companies regarding this drug?
Development of long-acting formulations, biosimilar entry, and expanding indications into oncology or other therapeutic areas can offer growth avenues.
5. How do insurance companies influence the final consumer price of NDC 00054-0283?
Insurance reimbursement rates and formulary decisions significantly impact out-of-pocket costs, potentially dictating market prices and access levels.
References
[1] Expert Market Research. "Global Hormone Therapy Market." 2022.
[2] Red Book. "Average Wholesale Prices for Medroxyprogesterone Acetate." 2023.
[3] FDA Approvals Database. "Biosimilar Approvals and Patent Data." 2022.
[4] IQVIA Data. "Market Trends in Reproductive Health and Hormone Therapy." 2022.
[5] Marketing and Regulatory Reports. "Impact of Patents and Biosimilars on Pricing." 2023.
Note: All prices and data are estimations subject to regional variations and changing market conditions.
More… ↓
